Rett Syndrome Clinical Trials Review: An Updated Status Report on Emerging Drugs by DelveInsight

19 Apr 2021
www.globenewswire.com
Priority Review
Los Angeles, USA , April 19, 2021 (GLOBE NEWSWIRE) -- Rett Syndrome Clinical Trials Review: An Updated Status Report on Emerging Drugs by DelveInsight The report offers the most up-to-date information on Rett Syndrome pipeline products being developed by notable companies such as Anavex Life Sciences Corp., GW Research Ltd, Neuren Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Edison Pharmaceuticals, Novartis, Neurolixis, Echo Pharmaceuticals, Relmada Therapeutics, and others. DelveInsight’s “Rett Syndrome Pipeline Insight” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Rett Syndrome pipeline landscapes. It comprises Rett Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Rett Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Rett Syndrome pipeline products. Some of the key takeaways of the Rett Syndrome Pipeline Report Get an overview of pipeline landscape @ Rett Syndrome Clinical Trials Analysis Rett Syndrome is a neurodevelopmental disorder, which affects girls almost exclusively. It is characterised by average early growth and development followed by a decrease of development, loss of purposeful use of the hands, distinctive hand movements, decreased brain and head growth, walking, seizures, and intellectual disability. There is no cure for the disease. Rett Syndrome treatment is symptomatic, focusing on managing symptoms and supportive, needing a multidisciplinary approach. Medication may be required for breathing irregularities and motor difficulties, and anticonvulsant drugs may be utilised to control seizures. Occupational therapy can benefit children develop skills required for performing self-directed activities, while physical therapy and hydrotherapy may prolong mobility. Rett Syndrome Emerging Drugs Trofinetide is a novel synthetic analogue of the amino‐terminal tripeptide of IGF-1 designed to treat the core symptoms of Rett Syndrome by reducing neuroinflammation and supporting synaptic function. Research and Development Phase III NCT04181723: ACADIA Pharmaceuticals, in November 2019, initiated a Phase III study titled “Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Trofinetide for the Treatment of Girls and Women with Rett Syndrome”. With an estimated 184 participants, the trial is currently in recruiting stage and expected to be completed by October 2021. Neuren's North American partner for trofinetide, ACADIA Pharmaceuticals, has commenced a Phase 3 trial ("Lavender") in Rett syndrome. Neuren previously conducted a Phase 2 double-blind placebo-controlled clinical trial in girls aged 5 to 15 years with Rett syndrome. This followed positive trends observed in Neuren's earlier Phase 2 trial in adolescents and adults aged 16 to 45 years. For further information, refer to the detailed report @ Rett Syndrome Pipeline Therapeutics Scope of Rett Syndrome Pipeline Drug Insight Key Questions regarding Current Rett Syndrome Treatment Landscape and Emerging Therapies Answered in the Pipeline Report Table of Contents Get a customised pipeline report @ Rett Syndrome Drugs Pipeline Report Related Reports DelveInsight's Rett Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Rett Syndrome - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Rett Syndrome in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. DelveInsight's Acute Coronary Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Aicardi Goutieres Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Alagille Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.